Phase 1 Trial: GDC-2992, A Novel Dual-Action AR Degrader Aiming to Overcome Resistance in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 17/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This is AACR 2025 week, and there’s a lot to talk about regarding new treatments for solid tumors that could potentially include prostate cancer. Studies directly focused on prostate cancer have not yet been fully revealed, but I’ve already […]
Phase 1 Recruiting: IMP1734 (EIK1003), A New PARP1 Inhibitor for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxGrape Seed Extract Shows Potential to Slow Prostate Cancer Progression
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxOvercoming Resistance in Metastatic Prostate Cancer: Repurposing Pimitespib
/in Drug repurposing, Preclinical Research/by MaxBA1106 Antibody Shows Promise in Early Trials In Solid Tumors
/in Clinical Trial, Not PCa related/by MaxQ702 Drug Shows Promise in Early Trials: Could Be Useful Against Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxNezastomig (REGN5678): New Drug Combo Shows Promise In mCRPC, But Safety Is A Concern
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 35/2026 August 30, 2026
- Soon to Be Phase 1: ADI‑212 Off The Shelf CAR T Therapy for mCRPC August 28, 2026
- Daily Adaptive Radiotherapy After Prostate Surgery: Early Results from the DART-PHASER Study August 27, 2026
- Forcing Resistant Prostate Cancer Back into Treatment Range: eIF4E Could Help August 27, 2026